8 hours ago
1
JHVEPhoto
Shares of UroGen Pharma (NASDAQ:URGN) lost ~47% on Wednesday after an FDA advisory committee voted against the company’s bladder cancer therapy UGN-102 (mitomycin), which is currently under regulatory review in the U.S.
On the question of the risk-benefit profile of
English (US) ·